This chapter offers a unique perspective on shareholder litigation, describing the authors’ experience as plaintiffs in a transformative securities class action lawsuit in Israel. Israel-based Teva is the world’s largest manufacturer of generic drugs and is crosslisted in both the United States and Israel. The company reported its executive compensation in the aggregate rather than individually, using its crosslisted status to avoid what the authors viewed as a straightforward requirement of both US and Israeli law. In contrast, companies listed only in Israel disclosed individual executive pay, and were therefore the only companies subject to media scrutiny of their compensation practices. The authors’ class action eventually led to the requirement that all publicly traded Israeli companies disclose the compensation of each executive individually, regardless of whether a company is crosslisted.
Ehud Kamar, Ayal Shenhav and Shay Yanovsky
This chapter offers an insight into start-up law in Israel, by looking into its regulatory framework, practice and jurisprudence. Chapter brings a unique set of practices and regulation of start-ups in Israel, focusing predominantly on corporate law, start-up financing, tax law, IP protection and some specific areas that are considered elemental for start-up life in Israel. This chapter provides a reader with an analysis of the Israeli start-up environment and the start-up industries. The offered insights anticipate start-up’s legal concerns from its inception to its liquidation or bankruptcy.